About HemaQuest
Founders
Douglas V. Faller, Ph.D., M.D.
Dr. Faller's research efforts have focused on the role of viruses and oncogenes in cancer and cell growth. He is an inventor of several of HemaQuest's technologies, including the discoveries related to viral-associated malignancies. Dr. Faller is Director of the Cancer Research Center at Boston University School of Medicine and Director of Cancer Programs at Boston Medical Center. He is also Vice-Chairman of the Department of Medicine and Professor of Medicine, Biochemistry, Pediatrics, Microbiology, Pathology and Laboratory Medicine. Dr. Faller directs national and institutional clinical trials in oncology, including 75 ongoing clinical trials. Dr. Faller is the recipient of multiple awards and honors. He has multiple patents or patent applications for cancer therapeutics or diagnostics, and has over 300 research publications. Dr. Faller received his M.D. from Harvard Medical School and his Ph.D. from the Massachusetts Institute of Technology. He received his post-graduate residency and subspecialty training in Hematology and Oncology at the University of California San Francisco, Boston Children's Hospital, Brigham and Women's Hospital, the Dana-Farber Cancer Institute, and Harvard Medical School, where he was previously on the faculty in the Department of Medicine.
Thalia Papayannopoulou, M.D.
Dr. Papayannopoulou is internationally recognized for her work in hematopoiesis, stem cell biology, and globin gene regulation. She has more than 200 research publications. Her research led to the discovery of mechanisms of activation of fetal hemoglobin and to the introduction of cytotoxic drugs including hydroxyurea in the treatment of sickle cell disease. Dr. Papayannopoulou is Professor of Medicine in the Division of Hematology at the University of Washington, the recipient of the William Dameshek Prize of the American Society of Hematology, a former member of the National Advisory Council at the National Heart, Lung and Blood Institute, and a member of the American Academy of Arts and Sciences. She is the President Elect of the International Society of Experimental Hematology and an associate editor of the Journal of Experimental Hematology. Dr. Papayannopoulou received her M.D. from the University of Athens. Her post-graduate training was carried out in the Department of Pathology and the Division of Hematology/Department of Medicine, at the University of Washington.
George Stamatoyannopoulos, M.D., D.Sc.
Dr. Stamatoyannopoulos has more than 400 research publications and is widely acknowledged as a leader of the field of hemoglobinopathies. For over four decades his research has focused on the delineation of the cellular and molecular processes by which hemoglobin switches from fetal to adult hemoglobin during development. At the University of Washington, Dr. Stamatoyannopoulos is Professor in the Departments of Medicine, Pathology and Genome Sciences, and the Director of the Markey Molecular Medicine Center. Dr. Stamatoyannopoulos has been the recipient of several honors and awards, including the William Dameshek Prize and the Stratton Medal of the American Society of Hematology, the Metcalf Prize of the International Society of Experimental Hematology, and the Levine Prize of the American Society of Clinical Pathology. He has served as President of the American Society of Hematology and he is the founding President of the American Society of Gene Therapy. He has founded two other biotechnology companies, Targeted Genetics and Regulome. Dr. Stamatoyannopoulos received his M.D. from the University of Athens and his Doctor of Science degree from the University of Athens. His post-graduate training was in the Department of Clinical Therapeutics at the University of Athens Medical School and at the Royal Hellenic Research Foundation.
Robert M. Williams, Ph.D.
Dr. Williams is a leading medicinal chemist, who is an expert in designing and synthesizing novel small-molecules for therapeutic applications in hematology and oncology. Since September 1980, Professor Williams has served as a Professor of Chemistry at Colorado State University, and, in 2001, he was appointed University Distinguished Professor. He was a founder and served on the Board of Directors and Scientific Advisory Board of Xcyte Therapies. During his career, Professor Williams has provided consulting services to several biotechnology and pharmaceutical companies, including Cubist Pharmaceutical Company, Microcide Pharmaceuticals, Hoffman-La Roche, G.D. Searle, and EPIX Medical, Inc. Professor Williams received a Ph.D. in organic chemistry from the Massachusetts Institute of Technology. Following graduate school, Professor Williams served as a postdoctoral fellow at Harvard University.